Rebound Weight Gain Common After Discontinuing Antiobesity Medications
By Elana Gotkine HealthDay Reporter
FRIDAY, July 25, 2025 -- Antiobesity medications (AOMs) yield weight loss during use, followed by weight regain after discontinuation of treatment, according to a review published online July 21 in BMC Medicine.
Han Wu, from the Peking University People's Hospital in Beijing, and colleagues conducted a systematic review to explore the long-term effects of AOMs on body weight. The review included randomized controlled trials of AOMs conducted within populations for at least four weeks and followed for four or more weeks after discontinuation. Weight change was reported during drug treatment and after drug discontinuation.
The researchers found that compared with the control group, AOM treatment had weight loss effects at week 4 after discontinuation (weighted mean difference, −0.32 kg; 95 percent confidence interval, −3.60 to 2.7; P = 0.85). Compared with the control group, AOMs were associated with significant weight regain at eight weeks after drug discontinuation (weighted mean difference, 1.50 kg; 95 percent confidence interval, 1.32 to 1.68; P < 0.0001), a trend that continued through 12 and 20 weeks. Significant weight regain after 12 weeks of drug discontinuation was only seen in studies with glucagon-like peptide 1 receptor agonist-related drugs. Significant weight gain after drug discontinuation was seen in studies in which weight loss was greater during treatment than in the control group and in studies in which lifestyle interventions were continued.
"According to the trajectory of weight regain, body weight continued to decrease within four weeks after treatment discontinuation and then started to show a gradually increasing trend after eight weeks," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted July 2025
Read this next
Patients Face High Out-of-Pocket Costs After Incident Cancer Diagnosis
FRIDAY, July 25, 2025 -- Patients face high out-of-pocket costs (OOPCs) after an incident diagnosis of cancer, with costs increasing with stage of diagnosis, according to a study...
Exposure to PFAS Mixtures Linked to Increased Odds of Type 2 Diabetes
FRIDAY, July 25, 2025 -- In multiethnic populations, exposure to per- and polyfluoroalkyl substance (PFAS) mixtures may be associated with increased odds of type 2 diabetes (T2D)...
More Than Half of Infants Diagnosed With HIV Did Not Receive Postnatal HIV Prophylaxis
THURSDAY, July 24, 2025 -- Although the rate of perinatal HIV infection is low, more than 50 percent of HIV infections in infants before age 1 year occurred in those who did not...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.